Body mass index–associated differences in response to ovulation induction with letrozole  

Oleh:

McKnight, Katherine K. ; Nodler, James L. ; Cooper, John J. ; Chapman, Victoria R.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 96 no. 05 (Nov. 2011), page 1206-1208.
Topik: Letrozole; body mass index; ovulation induction; intrauterine insemination; aromatase inhibitor

Ketersediaan

Perpustakaan FK Nomor Panggil: F02.K.2011.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Objective To compare occurrence of pregnancy among obese (body mass index [BMI] =30) and nonobese (BMI <30), infertile women undergoing ovulation induction with the aromatase inhibitor letrozole followed by intrauterine insemination (IUI). Design Retrospective cohort study. Setting Academic reproductive endocrinology and infertility clinic. Patient(s) Ninety women with a variety of infertility diagnoses. Intervention(s) Letrozole (5 mg) on menstrual cycle days 3–7, followed by intrauterine insemination (IUI). Main Outcome Measure(s) Occurrence of pregnancy and pregnancy outcomes. Result(s) Ninety women underwent 180 letrozole-IUI cycles. Conception of pregnancy occurred in 10.4% and 18.2% of the BMI <30 and BMI =30 groups, respectively. Using BMI as a continuous variable showed a pregnancy odds ratio of 1.093 (confidence interval 1.008–1.184) for each unit increase in BMI. Incidence of miscarriage, multiple births, number of mature follicles, and presence of LH surge were similar between groups. Conclusion(s) Our study of 90 women undergoing letrozole-IUI treatment showed greater likelihood of pregnancy in higher-BMI women, although the difference was not significant. Letrozole is an effective ovulation induction agent in higher-BMI women.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali